Skip to main content
Erschienen in: Supportive Care in Cancer 11/2009

01.11.2009 | Original Article

Longitudinal oncology registry of head and neck carcinoma (LORHAN®): initial supportive care findings

verfasst von: Barbara A. Murphy, Amy Chen, Walter J. Curran Jr., Adam S. Garden, Paul M. Harari, Stuart J. Wong, K. Kian Ang

Erschienen in: Supportive Care in Cancer | Ausgabe 11/2009

Einloggen, um Zugang zu erhalten

Abstract

Goals of work

We report the first analysis of demographic, socioeconomic, and toxicity data from the Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN).

Materials and methods

Eligible patients include newly diagnosed Head and Neck Cancer (HNC) patients, scheduled to receive radiotherapy or drug therapy, ≥18 years of age, and able to provide informed consent. Assessments are completed at baseline, at the completion of therapy, and yearly thereafter. Patient data are entered in the registry electronically and transferred via Secure HTTP protocols.

Results

Reported use of supportive care differed by treatment setting. When compared to community sites, patients at academic centers received more supportive interventions: feeding tube (59% vs. 48%; p = 0.001), tracheotomy tube (16% vs. 9%; p = 0.002), opioid analgesics (89% vs. 59%; p < 0.0001), anti-emetics (83% vs. 68%; p < 0.0001), and amifostine (17% vs. 12%; p = 0.02). Reported grades 3–4 mucositis/stomatitis was also higher in patients treated at academic centers (38% vs. 28%; p = 0.001).

Conclusion

There was a marked decrease in the documented use of supportive care measures in the community setting. This may be due to (1) lower rates of toxicity requiring less supportive care, (2) less stringent documentation, or (3) less aggressive use of supportive care measures. The documented rate of mucositis was less than expected. This is likely due to inadequate assessment or documentation. Further exploration of these findings is warranted as they may indicate an under appreciation and undertreatment of clinically significant acute tumor and treatment-related toxicities.
Literatur
1.
Zurück zum Zitat Adelstein DJ, Adams G, Wagner H, Kish JA, Ensley JF, Schuller DE, Forastiere A (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92–98 doi:10.1200/JCO.2003.01.008 CrossRefPubMed Adelstein DJ, Adams G, Wagner H, Kish JA, Ensley JF, Schuller DE, Forastiere A (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92–98 doi:10.​1200/​JCO.​2003.​01.​008 CrossRefPubMed
2.
Zurück zum Zitat Forastiere A, Berkey B, Maor M (2001) Phase III trial to preserve the larynx: induction chemotherapy and radiotherapy versus concomitant chemotherapy versus radiotherapy alone, intergroup trial R91–11. Proc Amer Soc Clin Oncol 20:2a, abstract # 4 Forastiere A, Berkey B, Maor M (2001) Phase III trial to preserve the larynx: induction chemotherapy and radiotherapy versus concomitant chemotherapy versus radiotherapy alone, intergroup trial R91–11. Proc Amer Soc Clin Oncol 20:2a, abstract # 4
3.
Zurück zum Zitat Bonner JA, Harari P, Giralt N, Azaria R, Cohen D, Raben C, Jones MS, Kies MS, Baselga J, Ang KK, Phase III study of high dose radiation with or without cetuximab in the treatment of locoregionally advanced squamous cell cancer of the head and neck. Proc Amer Soc Clin Oncol 204. 23: p. late breaking abstract Bonner JA, Harari P, Giralt N, Azaria R, Cohen D, Raben C, Jones MS, Kies MS, Baselga J, Ang KK, Phase III study of high dose radiation with or without cetuximab in the treatment of locoregionally advanced squamous cell cancer of the head and neck. Proc Amer Soc Clin Oncol 204. 23: p. late breaking abstract
4.
Zurück zum Zitat El-Sayed S, Nelson N (1996) Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. Clin Oncol 14:838–847 El-Sayed S, Nelson N (1996) Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. Clin Oncol 14:838–847
5.
Zurück zum Zitat Murphy BA et al (2007) Symptom control issues and supportive care of patients with head and neck cancers. Clin Adv Hematol Oncol 5(10):807–822PubMed Murphy BA et al (2007) Symptom control issues and supportive care of patients with head and neck cancers. Clin Adv Hematol Oncol 5(10):807–822PubMed
6.
Zurück zum Zitat Murphy BA, Chen A, Harari P, Curran W, Wong S, Bellm L, Gamber D, Dawson D, Garden A, Ang K (2007) Longitudinal oncology registry of head and neck carcinoma: (LORHAN), A new national cancer registry. Proceedings Multidisciplinary Head and Neck Cancer Symposium, p. Presentation #7. Murphy BA, Chen A, Harari P, Curran W, Wong S, Bellm L, Gamber D, Dawson D, Garden A, Ang K (2007) Longitudinal oncology registry of head and neck carcinoma: (LORHAN), A new national cancer registry. Proceedings Multidisciplinary Head and Neck Cancer Symposium, p. Presentation #7.
10.
Zurück zum Zitat Fee WE Jr (1999) Surgery in the aging population. Arch Otolaryngol Head Neck Surg 125(12):1405, discussion 1406–7PubMed Fee WE Jr (1999) Surgery in the aging population. Arch Otolaryngol Head Neck Surg 125(12):1405, discussion 1406–7PubMed
19.
Zurück zum Zitat Piccirillo JF et al (2002) Development of a new head and neck cancer-specific comorbidity index. Arch Otolaryngol Head Neck Surg 128(10):1172–1179PubMed Piccirillo JF et al (2002) Development of a new head and neck cancer-specific comorbidity index. Arch Otolaryngol Head Neck Surg 128(10):1172–1179PubMed
20.
Zurück zum Zitat Breitbart W, Holland J (1988) Psychosocial aspects of head and neck cancer. Semin Oncol 15(1):61–69PubMed Breitbart W, Holland J (1988) Psychosocial aspects of head and neck cancer. Semin Oncol 15(1):61–69PubMed
22.
Zurück zum Zitat Rapoport Y, Kreitler S, Chaitchik S, Algor R, Weissler K (1993) Psychosocial problems in head-and-neck cancer patients and their change with time since diagnosis. Ann Oncol 4(1):69–73PubMed Rapoport Y, Kreitler S, Chaitchik S, Algor R, Weissler K (1993) Psychosocial problems in head-and-neck cancer patients and their change with time since diagnosis. Ann Oncol 4(1):69–73PubMed
23.
Zurück zum Zitat Devine D, Parker P, Fouladi RT, Cohen L (2003) The association between social support, intrusive thoughts, avoidance, and adjustment following an experimental cancer treatment. Psychooncology 12(5):453–462 doi:10.1002/pon.656 CrossRefPubMed Devine D, Parker P, Fouladi RT, Cohen L (2003) The association between social support, intrusive thoughts, avoidance, and adjustment following an experimental cancer treatment. Psychooncology 12(5):453–462 doi:10.​1002/​pon.​656 CrossRefPubMed
24.
Zurück zum Zitat Hassanein KA, Musgrove B, Bradbury E (2001) Functional status of patients with oral cancer and its relation to style of coping, social support and psychological status. Br J Oral Maxillofac Surg 39(5):340–345 doi:10.1054/bjom.2001.0652 CrossRefPubMed Hassanein KA, Musgrove B, Bradbury E (2001) Functional status of patients with oral cancer and its relation to style of coping, social support and psychological status. Br J Oral Maxillofac Surg 39(5):340–345 doi:10.​1054/​bjom.​2001.​0652 CrossRefPubMed
26.
Zurück zum Zitat Murphy BA (2007) Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. J Support Oncol 5(9 Suppl 4):13–21PubMed Murphy BA (2007) Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. J Support Oncol 5(9 Suppl 4):13–21PubMed
27.
Zurück zum Zitat Trotti A, Bellm L, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysnyk L, Zilbergerg MD (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66:253–262 doi:10.1016/S0167–8140(02)00404–8 CrossRefPubMed Trotti A, Bellm L, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysnyk L, Zilbergerg MD (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66:253–262 doi:10.​1016/​S0167–8140(02)00404–8 CrossRefPubMed
Metadaten
Titel
Longitudinal oncology registry of head and neck carcinoma (LORHAN®): initial supportive care findings
verfasst von
Barbara A. Murphy
Amy Chen
Walter J. Curran Jr.
Adam S. Garden
Paul M. Harari
Stuart J. Wong
K. Kian Ang
Publikationsdatum
01.11.2009
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 11/2009
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0596-4

Weitere Artikel der Ausgabe 11/2009

Supportive Care in Cancer 11/2009 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.